TSOI CTE / TBI and related Info

Post Reply
User avatar
TimGDixon
Posts: 1073
Joined: Fri Jun 26, 2020 4:36 am

TSOI CTE / TBI and related Info

Post by TimGDixon »

I couldn't figure out how to move your original post to here but the topic is too big for a single thread and needs its own forum. Below is Traders original post.

TSOI has several products Re: CTE , and TBI . This is the place to share info that is related .

Videos on CTE /TBI include
1) Video interview with NFL veteran Terry LeCount , and NeuroStilbene .
2) Video interview with NFL veteran Bobby Duckworth .
3) Video interview with Dr. Thomas Ichim, Dr. James Veltmeyer, and TSOI CEO Tim Dixon .


https://www.wcteinc.org/alzheimers


4) Video Interview with NFL Veteran Wes Chandler on CTE / TBI

https://www.wcteinc.org/
trader32176
Posts: 2590
Joined: Fri Jun 26, 2020 5:22 am

Re: TSOI CTE / TBI and related Info

Post by trader32176 »

no prob Tim,
besides the videos , i will be adding the most up to date info here - along with others on CTE and TBI .

The videos I posted earlier give a background from pro football players experiences w/ TBI , and CTE , and NeuroStilBene . but now it's time to step back into the past several years to start my latest journey . this is like hiking outdoors , and I will do my best to help guide us all along again .

The earlier info on TBI , and CTE goes back several years , and those that want to catch up , should read up on these links before we even get to where TSOI is in their research and development of products related to TBI /CTE :

i believe It started in 2002 w/ an autopsy done by Dr. Bennet Omalu :

How the Discovery of CTE Shifted Thinking Behind Concussion Protocol
When Bennet Omalu, MD, identified a degenerative brain disease in NFL players, it shifted the worlds of both sports and neurology.


https://www.brainandlife.org/articles/w ... isease-in/

Concussion
was a movie made about concussions , and CTE in 2015 :

https://www.imdb.com/title/tt3322364/

and CTE was brought into the mainstream news again from this Boston University Study :

CTE Found in 99 Percent of Former NFL Players Studied
Data suggest disease may be more common in football players than previously thought


http://www.bu.edu/articles/2017/cte-for ... -players/v

The NY Times and Sports Illustrated ran stories on CTE BU Study right afterwards :

https://www.nytimes.com/interactive/201 ... l-cte.html

https://www.si.com/nfl/2017/07/25/bosto ... yer-brains


TSOI began filing CTE, and TBI patents
2018 :

https://therapeuticsolutionsint.com/patents/

09-17-18 Pterostilbene and Compositions Thereof for Prevention and Treatment of Chronic Traumatic Encephalopathy

12-05-18
Treatment of Chronic Traumatic Encephalopathy via RNA Administration

On Dec 6,2018 , this data was announced :

Therapeutic Solutions International Expands Chronic Traumatic Encephalopathy Intellectual Property Portfolio

New Data Demonstrates Ability of Immune System to Alter Football Related Brain Injuries

(I'll put the actual PR in my next post)


TSOI licensed a JadiCell product on Dec 10, 2018 :


Therapeutic Solutions International Signs Agreement for Licensing Jadi Cell's Universal Donor Adult Stem Cell Product for Chronic Traumatic Encephalopathy and Traumatic Brain Injury
Company intends to use Stem Cells under new Right to Try law for CTE

https://www.globenewswire.com/news-rele ... Injur.html

More TSOI CTE patent filings:

01-09-19 Autologous Neurogenic Cells and Uses Thereof for Professional Athletes at Risk of Chronic Traumatic Encephalopathy

01-21-19
Prevention and Reversion of Chronic Traumatic Encephalopathy through Administration of “Educated” Monocytes and Progenitors Thereof
trader32176
Posts: 2590
Joined: Fri Jun 26, 2020 5:22 am

Re: TSOI CTE / TBI and related Info

Post by trader32176 »

Therapeutic Solutions International Expands Chronic Traumatic Encephalopathy Intellectual Property Portfolio

New Data Demonstrates Ability of Immune System to Alter Football Related Brain Injuries


http://ih.advfn.com/stock-market/USOTC/ ... nds-chroni

OCEANSIDE, CA -- December 06, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today data demonstrating that modification of certain elements of the immune response can alter brain function in models of Chronic Traumatic Encephalopathy (CTE).

The Company filed a patent covering the use of specific molecules which activate parts of the immune system, which are usually associated with suppressing brain function, as a means of protecting from injury associated with multiple hits to the brain. The data is very contradictory to what is expected, and therefore, in the opinion of the Company, likely to result in issuance of the patent that was filed.

"It is widely recognized that immune modulation is a mechanism by which many interventions in the area of neurology work. For example, in animal models, removal of immune organs abrogates the ability of stem cells and their soluble mediators to ameliorate the neurological impact of stroke1" said Thomas Ichim, Board Member of the Company and Co-Inventor of the Patent. "It is not a coincidence, in my opinion, that out of all the systems of the body, only the immune system, and the nervous system possess memory, self, non-self-recognition, and the ability to possess specificity to an extremely high degree."

The Company, through its academic collaborators, demonstrated not only ability of mesenchymal stem cells to reverse chronic traumatic encephalopathy in animal models, but observed the very paradoxical finding that treating the stem cells with chemicals associated with brain damage, endows enhanced therapeutic activity to the stem cells.

"The current data, in my opinion, is very rational. If stem cells were constantly active, they would be expending energy for nothing" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "It is conceptually logical that by exposing stem cells to molecular signals which mimic injury, that the stem cells will possess enhanced therapeutic activity."

By stimulating the TLR3 arm of the immune system and demonstrating reduction of brain damage subsequent to multiple sub-acute chronic injuries, but not in single acute injuries such as stroke, the Company believes it has identified major differences between the chronic traumatic encephalopathy which occurs in sports (which is many small hits over time), in contrast to traumatic brain injury or situations in which one major event leads to brain damage.

"We are in an ideal position in that our NeuroStilbene product, appears to possess prophylactic properties, and we are currently working on therapeutic approaches to the problem of Chronic Traumatic Encephalopathy," said Tim Dixon CEO of the Company and Co-Inventor. "These sub-acute brain injuries are not only associated with NFL football players but also our military, which in some cases predisposes them to PTSD2."
trader32176
Posts: 2590
Joined: Fri Jun 26, 2020 5:22 am

Re: TSOI CTE / TBI and related Info

Post by trader32176 »

so , after December 2018 , on january 9,2019 TSOI announced :

Therapeutic Solutions International Continues to Expand Chronic Traumatic Encephalopathy Intellectual Property Portfolio

Patent filed for Autologous Neurogenic Cells in Professional Athletes at Risk of CTE


http://ih.advfn.com/stock-market/USOTC/ ... inues-to-e

OCEANSIDE, CA -- January 09, 2019 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the addition and expansion to their CTE portfolio of intellectual property with the filing of a new patent application.

The invention pertains to the field of cellular therapies, more particularly, the invention pertains to the use of banking of autologous cells, and the manipulation of autologous cells for treatment of CTE.

CTE is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe.

"This new means of obtaining autologous cells and banking them for use in the treatment and prevention of CTE is a new and novel approach. The autologous regenerative cells are banked for future administration in the same patient when the patient begins to develop signs of CTE or possesses an upregulation of markers associated with the probability of CTE onset" said Tim G Dixon CEO & President of Therapeutic Solutions International, Inc.

"Banking of autologous cells is a well-known procedure which has generated considerable revenue despite little practical value. For example, the only FDA approved means of utilizing cord blood cells is for treatment of pediatric leukemias, however, in these situations, allogeneic cells are required due to the possibility of autologous cells possessing proclivity towards leukemic transformation. The current patent provides tissue banking means for athletes at risk of CTE and means of utilizing the autologous cells" said Dr. Thomas Ichim, Board Member of Therapeutic Solutions International. "The possibility of using regenerative cells such as stem cells is limited by a lack of autologous cell sources. Our invention provides means of banking and utilizing autologous cells for use in patients with CTE."
trader32176
Posts: 2590
Joined: Fri Jun 26, 2020 5:22 am

Re: TSOI CTE / TBI and related Info

Post by trader32176 »

Patent Filed For Banking Of Autologous Neurogenic Cells In Professional Athletes At Risk Of CTE

1/21/19


https://www.biobanking.com/patent-filed ... sk-of-cte/

Therapeutics Solutions International, Inc., has announced the addition and expansion to their chronic traumatic encephalopathy (CTE) portfolio of intellectual property with the filing of a new patent application. The invention is in the field of cellular therapies, more particularly, the invention pertains to the use of autologous cell banking, and the manipulation of autologous cells for treatment of CTE.



Therapeutic Solutions International Obtains Exclusive License for Patented Clinical Stage Adult Stem Cell for Treatment of Military and Sports Brain Injuries


7/1/19


https://www.globenewswire.com/news-rele ... uries.html

TSOI announced recently signing of a license agreement providing exclusive rights to a patented [1] adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI).

The stem cell licensed, termed "JadiCell" is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability [2].

Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells.

"As a practicing physician, I witness firsthand the devastation caused in our Combat Veterans, as well as Professional Athletes, from CTE and TBI" said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. "Given that these cells are subject of a cleared FDA IND for another indication, we believe we are uniquely positioned to accelerate development of JadiCell's.

Suicide is a major cause of death in military veterans, approximately 20 deaths per day [3]. It is widely known that TBI and CTE are associated with increased propensity for suicide [4,5]. Furthermore, studies show that cytokines associated with brain inflammation, such as IL-6 and TNF-alpha are found in higher levels in patients with suicidal tendencies [6].

"Successful treatment of neuroinflammation is the Holy Grail of therapeutic neurology" said Dr. Santosh Kesari, MD, PhD, Director of Pacific Neurosciences Institute and Scientific Advisory Board Member of TSOI. "The fact that the JadiCell's are anti-inflammatory, neuroregenerative, and effectively cross the blood brain barrier, make these cells exciting candidates for addressing the urgent need in patients with TBI and CTE. I look forward to working alongside Timothy Dixon and his team to get this extremely promising therapeutic into the clinic."

"I am honored that a stem cell luminary as powerful as Dr. Amit Patel, the first physician to inject stem cells into the human heart, has entrusted our Company with his potent and promising technology as applied to brain injuries" said Timothy Dixon, President and CEO of TSOI. "We look forward to filing an IND for this technology before year end."


National Football League Veteran Wes Chandler Creates WCTE Inc. to Tackle Chronic Traumatic Encephalopathy

Newly Formed Biotechnology Company to Diagnose, intervene, and find a cure for a Major Cause of Depression and Suicide in Football Players


12/23/19

https://www.prnewswire.com/news-release ... 78902.html

Therapeutic Solutions International Enters into Multi-Million Dollar Master Sales Agreement
with WCTE, Inc.

Company Started by NFL Chargers Hall of Famer Wes Chandler Collaborates with TSOI to Provide Nutraceutical Approach to Chronic Traumatic Encephalopathy


12/23/19

http://ih.advfn.com/stock-market/USOTC/ ... rs-into-mu


Therapeutic Solutions International Reports Inhibition of Microglial Activation with NeuroStilbene

Recent Data Supports NeuroStilbene to Suppress Neural Inflammation, Induce Regeneration, and Protect Brain Cells from Death


Jan. 8, 2020

https://www.prnewswire.com/news-release ... 83513.html

TSOI reported today positive animal and human brain cell data demonstrating inhibition in microglial activation of IL-1 beta, IL-6, and TNF-a. NeuroStilbene was also shown to induce neurogenic growth factors and protected from peroxide and kainic-acid induced apoptosis.

NeuroStilbene is a diluted preparation of NanoStilbene and will soon be available from WCTE, Inc. whom we have recently engaged in a multi-million-dollar sales agreement. NanoStilbene is a Patented and highly concentrated nanoemulsion of nanoparticle pterostilbene, the active ingredient contained in both formulations.

Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe.

"This is very exciting data to see that NeuroStilbene administration in both animals and human cell lines preserves and stimulates the proliferation of endogenous neural stem cells under inflammatory conditions, while stimulating neurogenic growth factors: BDNF, NGF, FGF-1, FGF-2. To determine this, microglial were cultured with TNF-alpha to induce neurogenic growth factors for 48 hours in the presence of increasing concentrations of NeuroStilbene," said Dr. Thomas E. Ichim, Director.

"This data is phenomenal, and our Science Team is currently authoring the manuscript to be submitted for peer review as quickly as they can. We have now shown in these experiments that NeuroStilbene suppresses brain inflammation, protects brain neurons from death, stimulates the production of regenerative factors from microglial, and enhances the proliferation of endogenous brain stem cells at the same time at very low dosage," said Timothy G. Dixon, President, and CEO. "We continue to advance the cause of solving the CTE crisis while maximizing the potential of this little molecule pterostilbene that continues to deliver, welcome to 2020."



Therapeutic Solutions International Reports Positive Preclinical Data on JadiCell™ Universal Donor Stem Cell Therapy for Brain Injury

FDA Cleared Stem Cell is Being Utilized by TSOI as Therapeutic Candidate to Repair Damaged Brains


9/28/20


https://www.prnewswire.com/news-release ... 38937.html


TSOI reported today positive preclinical data demonstrating superior neuro-regenerative activity to other cell therapies such as mesenchymal stem cells. Using animal models, Company collaborators demonstrated stimulation of stem cell proliferation that reside in parts of the brain called the "dentate gyrus". Additionally, the Company reported protection of neurons from inflammation associated cell death as well as reduction of inflammatory proteins produced by brain cells called "microglia".

"These data, combined with the fact that the JadiCell has already been cleared by the FDA for clinical trials in other indications, strongly support the development of the JadiCell as a therapeutic candidate for treatment of brain injuries, including chronic traumatic encephalopathy," said Dr. James Veltmeyer, Chief Medical Officer of the Company and San Diego Top Doctor. "We are working with our team and consultants to assemble the Investigational New Drug (IND) Application with the FDA to begin clinical trials on this terrible condition."

"Brain injury in the form of Chronic Traumatic Encephalopathy is a major scourge on the bravest elements of our society: the veterans. It is estimated that approximately 1 suicide per hour occurs because of PTSD," said Famela Ramos, Former Congressional Candidate and Director of Business Development for Therapeutic Solutions International. "The fact that we are able to offer hope for this terrible condition has our whole team energized."

"To our knowledge, we are the first Company to integrate a cell therapy approach towards combatting suicide," said Kalina O'Connor Director of the Campbell Neurosciences Division of TSOI.

"Through tireless work of our Scientific Advisory Board and our collaborators, we are pleased to be moving towards filing with the FDA to begin a clinical trial which is the first of its kind. Currently there are no potentially curative approaches for Chronic Traumatic Encephalopathy," said Timothy Dixon, President and CEO of the Company.
EhrTSOI
Posts: 42
Joined: Thu Jul 09, 2020 9:22 am

Re: TSOI CTE / TBI and related Info

Post by EhrTSOI »

New traumatic brain injury test is 'game-changing,' concussion experts say


"In a world first, a newly authorized handheld device will allow doctors to detect traumatic brain injuries (TBIs) in under 15 minutes, potentially saving lives by dramatically shortening the time it takes to properly diagnose the issue."

https://abcnews.go.com/Health/traumatic ... card_image

Ehr
User avatar
TimGDixon
Posts: 1073
Joined: Fri Jun 26, 2020 4:36 am

Re: TSOI CTE / TBI and related Info

Post by TimGDixon »

Thats very interesting,,,
EhrTSOI wrote: Tue Jan 12, 2021 1:30 pm New traumatic brain injury test is 'game-changing,' concussion experts say


"In a world first, a newly authorized handheld device will allow doctors to detect traumatic brain injuries (TBIs) in under 15 minutes, potentially saving lives by dramatically shortening the time it takes to properly diagnose the issue."

https://abcnews.go.com/Health/traumatic ... card_image

Ehr
Post Reply